Beximco PharmaceuticalsLSE:BXP 69 Market Cap is £223.1 Mil as of Jul. 01, 2026. GuruFocus rates LSE:BXP with a GF Score™ of 69/100 and a GF Value™ of £0.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,022 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 62.04% on this metric.
Beximco Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 (£203.0 Mil) to Dec. 2025 (£189.6 Mil) but then
stayed the same
from Dec. 2025 (£189.6 Mil) to Mar. 2026 (£189.6 Mil).
Beximco Pharmaceuticals's annual market cap
increased
from Jun. 2023 (£158.4 Mil) to Jun. 2024 (£174.0 Mil) but then
declined
from Jun. 2024 (£174.0 Mil) to Jun. 2025 (£162.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Beximco Pharmaceuticals's Enterprise Value for Today is £235.5 Mil.
Beximco Pharmaceuticals (LSE:BXP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Beximco Pharmaceuticals Market Cap Related Terms
Beximco Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Beximco Pharmaceuticals's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (LSE:BXP) has a Market Cap of £223.1 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Beximco Pharmaceuticals and its competitors. According to the industry distribution chart, Beximco Pharmaceuticals ranks #388 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 38%.
Is Beximco Pharmaceuticals' Market Cap too high?
Beximco Pharmaceuticals' current Market Cap is £223.1 Mil. Based on the distribution chart, Beximco Pharmaceuticals ranks #388 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beximco Pharmaceuticals has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #388 out of 1022 companies for Market Cap. This puts Beximco Pharmaceuticals in the upper half of its industry. The industry median Market Cap is 210.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.16, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current Market Cap is £223.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (LSE:BXP) is currently considered Modestly Overvalued. The stock's GF Value™ is £0.45, compared to a current price of £0.50 — trading 11.1% above its estimated fair value. The current Market Cap is £223.1 Mil. Beximco Pharmaceuticals' overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Beximco Pharmaceuticals (LSE:BXP), the current Market Cap is £223.1 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beximco Pharmaceuticals (LSE:BXP) Overvalued in 2026?
Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued.
The current stock price of £0.50 is trading 11.1% above its estimated GF Value™ of £0.45.
GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LSE:BXP:
Market Cap: £223.1 Mil
GF Value™: £0.45 vs. price of £0.50 (11.1% above fair value)
No single metric tells the full story. See the LSE:BXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
69GF Score
Get the complete analysis for LSE:BXP
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BXP has been successfully added to your 
